Ocugen, Inc. OCGN shares are trading higher after the White House announced it would immediately make available specific raw materials needed by India to make COVID-19 vaccines.
Ocugen is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies. The company has a COVID-19 vaccine co-development partner, Bharat Biotech, which is located in India.
Ocugen's stock was trading approximately 19% higher to $11.44 on Monday at the time of publication. The stock has a 52-week high of $18.77 and a 52-week low of $0.17.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
